ZOLEDRONATE TRISODIUM

Details

Stereochemistry	ACHIRAL
Molecular Formula	5C5H7N2O7P2.15Na.2H2O
Molecular Weight	1726.2061
Optical Activity	NONE
Defined Stereocenters	0 / 5
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

O.O.[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].OC(CN1C=CN=C1)(P(O)([O-])=O)P([O-])([O-])=O.OC(CN2C=CN=C2)(P(O)([O-])=O)P([O-])([O-])=O.OC(CN3C=CN=C3)(P(O)([O-])=O)P([O-])([O-])=O.OC(CN4C=CN=C4)(P(O)([O-])=O)P([O-])([O-])=O.OC(CN5C=CN=C5)(P(O)([O-])=O)P([O-])([O-])=O

InChI

InChIKey=HYMYRPXSMHJPGD-UHFFFAOYSA-A

InChI=1S/5C5H10N2O7P2.15Na.2H2O/c5*8-5(15(9,10)11,16(12,13)14)3-7-2-1-6-4-7;;;;;;;;;;;;;;;;;/h5*1-2,4,8H,3H2,(H2,9,10,11)(H2,12,13,14);;;;;;;;;;;;;;;;2*1H2/q;;;;;15*+1;;/p-15

HIDE SMILES / InChI

Molecular Formula	HO
Molecular Weight	17.0073
Charge	-1
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C5H9N2O7P2
Molecular Weight	271.0817
Charge	-1
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	Na
Molecular Weight	22.9898
Charge	1
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/21386lbl.pdf

Zoledronic acid (Reclast, Aclasta, Zometa) is an intravenous, highly potent amino-bisphosphonate approved worldwide, including in the USA, EU and Japan for use in patients with primary or secondary osteoporosis or low bone mass (approved indications vary between countries). Its high affinity to and long half-life in bone, and long duration of action allow for once-yearly administration, which has the potential to improve adherence to therapy. Zoledronic acid once yearly for up to 3 years improved bone mineral density (BMD) at several skeletal sites, reduced fracture risk and bone turnover, and/or preserved bone structure and mass relative to placebo in clinical studies in patients with primary or secondary osteoporosis. While additional benefits were seen when treatment was continued for up to 6 years, as evidenced by a reduced risk of vertebral fractures and higher BMD relative to 3 years’ therapy, there was the minimal advantage of treatment beyond 6 years. Therefore, in patients with low fracture risk, treatment discontinuation should be considered after approximately 5 years’ therapy. Zoledronic acid administered annually or once in 2 years was also effective in preventing bone loss in patients with low bone mass. Zoledronic acid was generally well tolerated, with the most common adverse events (AEs) being transient, mild-to-moderate post-infusion symptoms, which decreased with subsequent infusions.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Farnesyl diphosphate synthase 28 Target ID: CHEMBL1782 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22390415	Inhibitor 8297	4.1 nM [IC50]
Geranylgeranyl pyrophosphate synthetase 18 Target ID: CHEMBL4769 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17535895	Inhibitor 8297	97.0 µM [IC50]
Carbonic anhydrase XIV 22 Target ID: CHEMBL3510 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24813742	Inhibitor 8297	92.0 nM [IC50]
Carbonic anhydrase II 88 Target ID: CHEMBL205 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24650641	Inhibitor 8297	62.0 nM [IC50]

Conditions

Condition	Modality	Highest Phase	Product
Hypercalcemia 21 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/21386lbl.pdf	Primary	Approved 8429	Zometa Approved Use INDICATIONS AND USAGE Hypercalcemia of Malignancy. Zometa® (zoledronic acid for injection) is indicated for the treatment of hypercalcemia of malignancy. Vigorous saline hydration, an integral part of hypercalcemia therapy, should be initiated promptly and an attempt should be made to restore the urine output to about 2 L/day throughout treatment. Mild or asymptomatic hypercalcemia may be treated with conservative measures (i.e., saline hydration, with or without loop diuretics). Patients should be hydrated dequately throughout the treatment, but overhydration, especially in those patients who have cardiac failure, must be avoided. Diuretic therapy should not be employed prior to correction of hypovolemia. The safety and efficacy of Zometa in the treatment of hypercalcemia associated with hyperparathyroidism or with other non-tumor-related conditions has not been established. Multiple Myeloma and Bone Metastases of Solid Tumors. Zometa is indicated for the treatment of patients with multiple myeloma and patients with documented bone metastases from solid tumors, in conjunction with standard antineoplastic therapy. Prostate cancer should have progressed after treatment with at least one hormonal therapy Launch Date 9.9817921E11
Disuse osteoporosis 9 Sources: https://clinicaltrials.gov/ct2/show/NCT02042872	Primary	Approved 8429	Zometa Approved Use INDICATIONS AND USAGE Hypercalcemia of Malignancy. Zometa® (zoledronic acid for injection) is indicated for the treatment of hypercalcemia of malignancy. Vigorous saline hydration, an integral part of hypercalcemia therapy, should be initiated promptly and an attempt should be made to restore the urine output to about 2 L/day throughout treatment. Mild or asymptomatic hypercalcemia may be treated with conservative measures (i.e., saline hydration, with or without loop diuretics). Patients should be hydrated dequately throughout the treatment, but overhydration, especially in those patients who have cardiac failure, must be avoided. Diuretic therapy should not be employed prior to correction of hypovolemia. The safety and efficacy of Zometa in the treatment of hypercalcemia associated with hyperparathyroidism or with other non-tumor-related conditions has not been established. Multiple Myeloma and Bone Metastases of Solid Tumors. Zometa is indicated for the treatment of patients with multiple myeloma and patients with documented bone metastases from solid tumors, in conjunction with standard antineoplastic therapy. Prostate cancer should have progressed after treatment with at least one hormonal therapy Launch Date 9.9817921E11
Prostate cancer with bone metastasis 9 Sources: https://clinicaltrials.gov/ct2/show/NCT00241111	Primary	Approved 8429	Zometa Approved Use INDICATIONS AND USAGE Hypercalcemia of Malignancy. Zometa® (zoledronic acid for injection) is indicated for the treatment of hypercalcemia of malignancy. Vigorous saline hydration, an integral part of hypercalcemia therapy, should be initiated promptly and an attempt should be made to restore the urine output to about 2 L/day throughout treatment. Mild or asymptomatic hypercalcemia may be treated with conservative measures (i.e., saline hydration, with or without loop diuretics). Patients should be hydrated dequately throughout the treatment, but overhydration, especially in those patients who have cardiac failure, must be avoided. Diuretic therapy should not be employed prior to correction of hypovolemia. The safety and efficacy of Zometa in the treatment of hypercalcemia associated with hyperparathyroidism or with other non-tumor-related conditions has not been established. Multiple Myeloma and Bone Metastases of Solid Tumors. Zometa is indicated for the treatment of patients with multiple myeloma and patients with documented bone metastases from solid tumors, in conjunction with standard antineoplastic therapy. Prostate cancer should have progressed after treatment with at least one hormonal therapy Launch Date 9.9817921E11
Renal osteodystrophy 11 Sources: https://clinicaltrials.gov/ct2/show/NCT01675089	Primary	Approved 8429	Zometa Approved Use INDICATIONS AND USAGE Hypercalcemia of Malignancy. Zometa® (zoledronic acid for injection) is indicated for the treatment of hypercalcemia of malignancy. Vigorous saline hydration, an integral part of hypercalcemia therapy, should be initiated promptly and an attempt should be made to restore the urine output to about 2 L/day throughout treatment. Mild or asymptomatic hypercalcemia may be treated with conservative measures (i.e., saline hydration, with or without loop diuretics). Patients should be hydrated dequately throughout the treatment, but overhydration, especially in those patients who have cardiac failure, must be avoided. Diuretic therapy should not be employed prior to correction of hypovolemia. The safety and efficacy of Zometa in the treatment of hypercalcemia associated with hyperparathyroidism or with other non-tumor-related conditions has not been established. Multiple Myeloma and Bone Metastases of Solid Tumors. Zometa is indicated for the treatment of patients with multiple myeloma and patients with documented bone metastases from solid tumors, in conjunction with standard antineoplastic therapy. Prostate cancer should have progressed after treatment with at least one hormonal therapy Launch Date 9.9817921E11
Postmenopausal osteoporosis 59 Sources: https://clinicaltrials.gov/ct2/show/NCT02499237	Primary	Approved 8429	Zometa Approved Use INDICATIONS AND USAGE Hypercalcemia of Malignancy. Zometa® (zoledronic acid for injection) is indicated for the treatment of hypercalcemia of malignancy. Vigorous saline hydration, an integral part of hypercalcemia therapy, should be initiated promptly and an attempt should be made to restore the urine output to about 2 L/day throughout treatment. Mild or asymptomatic hypercalcemia may be treated with conservative measures (i.e., saline hydration, with or without loop diuretics). Patients should be hydrated dequately throughout the treatment, but overhydration, especially in those patients who have cardiac failure, must be avoided. Diuretic therapy should not be employed prior to correction of hypovolemia. The safety and efficacy of Zometa in the treatment of hypercalcemia associated with hyperparathyroidism or with other non-tumor-related conditions has not been established. Multiple Myeloma and Bone Metastases of Solid Tumors. Zometa is indicated for the treatment of patients with multiple myeloma and patients with documented bone metastases from solid tumors, in conjunction with standard antineoplastic therapy. Prostate cancer should have progressed after treatment with at least one hormonal therapy Launch Date 9.9817921E11

C_max

Value	Dose	Co-administered	Analyte	Population
264 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/21563999	4 mg single, intravenous dose: 4 mg route of administration: Intravenous experiment type: SINGLE co-administered:		ZOLEDRONIC ACID plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
420 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/21563999	4 mg single, intravenous dose: 4 mg route of administration: Intravenous experiment type: SINGLE co-administered:		ZOLEDRONIC ACID plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
39 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/21563999	4 mg single, intravenous dose: 4 mg route of administration: Intravenous experiment type: SINGLE co-administered:		ZOLEDRONIC ACID plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

Doses

Dose	Population	Adverse events
16 mg 1 times / 4 weeks multiple, intravenous Highest studied dose Dose: 16 mg, 1 times / 4 weeks Route: intravenous Route: multiple Dose: 16 mg, 1 times / 4 weeks Sources: https://pubmed.ncbi.nlm.nih.gov/12412821	unhealthy, 40-79 years n = 12 Health Status: unhealthy Condition: cancer Age Group: 40-79 years Sex: M+F Population Size: 12 Sources: https://pubmed.ncbi.nlm.nih.gov/12412821	Sources: https://pubmed.ncbi.nlm.nih.gov/12412821
16 mg single, intravenous Highest studied dose Dose: 16 mg Route: intravenous Route: single Dose: 16 mg Sources: https://pubmed.ncbi.nlm.nih.gov/11148571	unhealthy, 54 years (range: 34–73 years) n = 10 Health Status: unhealthy Condition: cancer Age Group: 54 years (range: 34–73 years) Sex: M+F Population Size: 10 Sources: https://pubmed.ncbi.nlm.nih.gov/11148571	Other AEs: Skeletal pain, Fever... Other AEs: Skeletal pain (30%) Fever (20%) Anorexia (20%) Diarrhea (20%) Constipation (10%) Nausea (20%) Myalgia (20%) Arthralgia (10%) Anemia (30%) Rigors (20%) Coughing (20%) Leg edema (10%) Urinary tract infection (10%) Fatigue (40%) Sources: https://pubmed.ncbi.nlm.nih.gov/11148571

AEs

AE	Significance	Dose	Population
Arthralgia	10%	16 mg single, intravenous Highest studied dose Dose: 16 mg Route: intravenous Route: single Dose: 16 mg Sources: https://pubmed.ncbi.nlm.nih.gov/11148571	unhealthy, 54 years (range: 34–73 years) n = 10 Health Status: unhealthy Condition: cancer Age Group: 54 years (range: 34–73 years) Sex: M+F Population Size: 10 Sources: https://pubmed.ncbi.nlm.nih.gov/11148571
Constipation	10%	16 mg single, intravenous Highest studied dose Dose: 16 mg Route: intravenous Route: single Dose: 16 mg Sources: https://pubmed.ncbi.nlm.nih.gov/11148571	unhealthy, 54 years (range: 34–73 years) n = 10 Health Status: unhealthy Condition: cancer Age Group: 54 years (range: 34–73 years) Sex: M+F Population Size: 10 Sources: https://pubmed.ncbi.nlm.nih.gov/11148571
Leg edema	10%	16 mg single, intravenous Highest studied dose Dose: 16 mg Route: intravenous Route: single Dose: 16 mg Sources: https://pubmed.ncbi.nlm.nih.gov/11148571	unhealthy, 54 years (range: 34–73 years) n = 10 Health Status: unhealthy Condition: cancer Age Group: 54 years (range: 34–73 years) Sex: M+F Population Size: 10 Sources: https://pubmed.ncbi.nlm.nih.gov/11148571
Urinary tract infection	10%	16 mg single, intravenous Highest studied dose Dose: 16 mg Route: intravenous Route: single Dose: 16 mg Sources: https://pubmed.ncbi.nlm.nih.gov/11148571	unhealthy, 54 years (range: 34–73 years) n = 10 Health Status: unhealthy Condition: cancer Age Group: 54 years (range: 34–73 years) Sex: M+F Population Size: 10 Sources: https://pubmed.ncbi.nlm.nih.gov/11148571
Anorexia	20%	16 mg single, intravenous Highest studied dose Dose: 16 mg Route: intravenous Route: single Dose: 16 mg Sources: https://pubmed.ncbi.nlm.nih.gov/11148571	unhealthy, 54 years (range: 34–73 years) n = 10 Health Status: unhealthy Condition: cancer Age Group: 54 years (range: 34–73 years) Sex: M+F Population Size: 10 Sources: https://pubmed.ncbi.nlm.nih.gov/11148571
Coughing	20%	16 mg single, intravenous Highest studied dose Dose: 16 mg Route: intravenous Route: single Dose: 16 mg Sources: https://pubmed.ncbi.nlm.nih.gov/11148571	unhealthy, 54 years (range: 34–73 years) n = 10 Health Status: unhealthy Condition: cancer Age Group: 54 years (range: 34–73 years) Sex: M+F Population Size: 10 Sources: https://pubmed.ncbi.nlm.nih.gov/11148571
Diarrhea	20%	16 mg single, intravenous Highest studied dose Dose: 16 mg Route: intravenous Route: single Dose: 16 mg Sources: https://pubmed.ncbi.nlm.nih.gov/11148571	unhealthy, 54 years (range: 34–73 years) n = 10 Health Status: unhealthy Condition: cancer Age Group: 54 years (range: 34–73 years) Sex: M+F Population Size: 10 Sources: https://pubmed.ncbi.nlm.nih.gov/11148571
Fever	20%	16 mg single, intravenous Highest studied dose Dose: 16 mg Route: intravenous Route: single Dose: 16 mg Sources: https://pubmed.ncbi.nlm.nih.gov/11148571	unhealthy, 54 years (range: 34–73 years) n = 10 Health Status: unhealthy Condition: cancer Age Group: 54 years (range: 34–73 years) Sex: M+F Population Size: 10 Sources: https://pubmed.ncbi.nlm.nih.gov/11148571
Myalgia	20%	16 mg single, intravenous Highest studied dose Dose: 16 mg Route: intravenous Route: single Dose: 16 mg Sources: https://pubmed.ncbi.nlm.nih.gov/11148571	unhealthy, 54 years (range: 34–73 years) n = 10 Health Status: unhealthy Condition: cancer Age Group: 54 years (range: 34–73 years) Sex: M+F Population Size: 10 Sources: https://pubmed.ncbi.nlm.nih.gov/11148571
Nausea	20%	16 mg single, intravenous Highest studied dose Dose: 16 mg Route: intravenous Route: single Dose: 16 mg Sources: https://pubmed.ncbi.nlm.nih.gov/11148571	unhealthy, 54 years (range: 34–73 years) n = 10 Health Status: unhealthy Condition: cancer Age Group: 54 years (range: 34–73 years) Sex: M+F Population Size: 10 Sources: https://pubmed.ncbi.nlm.nih.gov/11148571
Rigors	20%	16 mg single, intravenous Highest studied dose Dose: 16 mg Route: intravenous Route: single Dose: 16 mg Sources: https://pubmed.ncbi.nlm.nih.gov/11148571	unhealthy, 54 years (range: 34–73 years) n = 10 Health Status: unhealthy Condition: cancer Age Group: 54 years (range: 34–73 years) Sex: M+F Population Size: 10 Sources: https://pubmed.ncbi.nlm.nih.gov/11148571
Anemia	30%	16 mg single, intravenous Highest studied dose Dose: 16 mg Route: intravenous Route: single Dose: 16 mg Sources: https://pubmed.ncbi.nlm.nih.gov/11148571	unhealthy, 54 years (range: 34–73 years) n = 10 Health Status: unhealthy Condition: cancer Age Group: 54 years (range: 34–73 years) Sex: M+F Population Size: 10 Sources: https://pubmed.ncbi.nlm.nih.gov/11148571
Skeletal pain	30%	16 mg single, intravenous Highest studied dose Dose: 16 mg Route: intravenous Route: single Dose: 16 mg Sources: https://pubmed.ncbi.nlm.nih.gov/11148571	unhealthy, 54 years (range: 34–73 years) n = 10 Health Status: unhealthy Condition: cancer Age Group: 54 years (range: 34–73 years) Sex: M+F Population Size: 10 Sources: https://pubmed.ncbi.nlm.nih.gov/11148571
Fatigue	40%	16 mg single, intravenous Highest studied dose Dose: 16 mg Route: intravenous Route: single Dose: 16 mg Sources: https://pubmed.ncbi.nlm.nih.gov/11148571	unhealthy, 54 years (range: 34–73 years) n = 10 Health Status: unhealthy Condition: cancer Age Group: 54 years (range: 34–73 years) Sex: M+F Population Size: 10 Sources: https://pubmed.ncbi.nlm.nih.gov/11148571

Overview

CYP3A4	CYP2C9	CYP2D6	hERG

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP450 25	CYP 270

Drug as perpetrator

Target	Modality	Activity	Metabolite	Clinical evidence
CYP450 41	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021817s000_PharmR_P1.pdf#page=50 Page: 50.0	no

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
CYP 270	substrate 3367 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5682380/	no

PubMed

Title	Date	PubMed
Zoledronic acid: an evolving role in the treatment of cancer patients with bone disease.	2001 Apr	11346864
Zoledronic acid in cancer patients with bone metastases: results of Phase I and II trials.	2001 Apr	11346862
Zoledronic acid in the treatment of hypercalcemia of malignancy: results of the international clinical development program.	2001 Apr	11346861
A Phase I, open label, dose ranging trial of intravenous bolus zoledronic acid, a novel bisphosphonate, in cancer patients with metastatic bone disease.	2001 Jan 1	11148571
Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials.	2001 Jan 15	11208851
Safety and efficacy of bisphosphonates beyond 24 months in cancer patients.	2001 Jul 15	11454892
[Bone metastasis. Can a new bisphosphonate offer control?].	2001 Mar 1	11288542
Advances in the biology and treatment of myeloma bone disease.	2001 Nov 15	11757204
The use of zoledronic acid, a novel, highly potent bisphosphonate, for the treatment of hypercalcemia of malignancy.	2002	12490736
FDA approves ZOMETA for treatment of cancer-related bone complications.	2002 Apr	12113230
Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity.	2002 Feb	11841428
New drugs 2002, part III.	2002 Jul	12352871
Zoledronate once-yearly increases bone mineral density--implications for osteoporosis.	2002 Jul	12083999
An investigation of bone resorption and Dictyostelium discoideum growth inhibition by bisphosphonate drugs.	2002 Jul 4	12086477
Zoledronic acid. A bisphosphonate for hypercalcemia of malignancy and osteolytic metastases.	2002 Jul-Aug	12100107
Bisphosphonates and osteoporosis.	2002 Jun 27	12087149
Bisphosphonates inhibit stromelysin-1 (MMP-3), matrix metalloelastase (MMP-12), collagenase-3 (MMP-13) and enamelysin (MMP-20), but not urokinase-type plasminogen activator, and diminish invasion and migration of human malignant and endothelial cell lines.	2002 Mar	11984068
The effect of bone remodeling inhibition by zoledronic acid in an animal model of cartilage matrix damage.	2002 Mar	11869084
Intravenous zoledronic acid in postmenopausal women with low bone mineral density.	2002 Oct	12356057
The IL-6 receptor super-antagonist Sant7 enhances antiproliferative and apoptotic effects induced by dexamethasone and zoledronic acid on multiple myeloma cells.	2002 Oct	12239628

Patents

Sample Use Guides

In Vivo Use Guide

The maximum recommended dose of Zometa in hypercalcemia of malignancy is 4 mg. The 4 mg dose must be given as a single-dose intravenous infusion over no less than 15 minutes.

Route of Administration: Intravenous

In Vitro Use Guide

For the transfection of the T24 human bladder cancer cells, pCMV6 empty vector (OriGene, Rockville, MD, USA) and pCMV6 TAp73 vector were transfected into cells using Lipofectamine™ 2000 (Invitrogen Life Technologies). After 6 h, the medium was refreshed and cultured for 48 h. Then the cells were treated with ZA (200 μM).

Substance Class	Chemical Created by `admin` on `Fri Dec 15 15:49:36 UTC 2023` Edited by `admin` on `Fri Dec 15 15:49:36 UTC 2023`
Record UNII	ARL915IH66
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

ZOLEDRONATE TRISODIUM

Official Name

English

ZOLEDRONATE TRISODIUM [MART.]

Common Name

English

ZOLEDRONIC ACID TRISODIUM SALT HYDRATE

Common Name

English

ZOLEDRONIC ACID TRISODIUM SALT HYDRATE [MI]

Common Name

English

CGP-42446B

Code

English

Trisodium hydrogen (1-hydroxy-2-imidazol-1-ylethylidene)diphosphonate, hydrate (5:2)

Common Name

English

CGP 42446B

Code

English

ZOLEDRONATE TRISODIUM [USAN]

Common Name

English

PHOSPHONIC ACID, (1-HYDROXY-2-(1H-IMIDAZOL-1-YL)ETHYLIDENE)BIS-, TRISODIUM SALT HYDRATE (5:2)

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C67439

Created by admin on Fri Dec 15 15:49:37 UTC 2023 , Edited by admin on Fri Dec 15 15:49:37 UTC 2023

NCI_THESAURUS

C443

Created by admin on Fri Dec 15 15:49:36 UTC 2023 , Edited by admin on Fri Dec 15 15:49:36 UTC 2023

Code System Code Type Description

USAN

II-4

Created by admin on Fri Dec 15 15:49:37 UTC 2023 , Edited by admin on Fri Dec 15 15:49:37 UTC 2023

PRIMARY

CAS

165800-08-8

Created by admin on Fri Dec 15 15:49:36 UTC 2023 , Edited by admin on Fri Dec 15 15:49:36 UTC 2023

PRIMARY

ChEMBL

CHEMBL924

Created by admin on Fri Dec 15 15:49:36 UTC 2023 , Edited by admin on Fri Dec 15 15:49:36 UTC 2023

PRIMARY

PUBCHEM

23725076

Created by admin on Fri Dec 15 15:49:37 UTC 2023 , Edited by admin on Fri Dec 15 15:49:37 UTC 2023

PRIMARY

DRUG BANK

DBSALT001758

Created by admin on Fri Dec 15 15:49:36 UTC 2023 , Edited by admin on Fri Dec 15 15:49:36 UTC 2023

PRIMARY

FDA UNII

ARL915IH66

Created by admin on Fri Dec 15 15:49:36 UTC 2023 , Edited by admin on Fri Dec 15 15:49:36 UTC 2023

PRIMARY

MERCK INDEX

m11658

Created by admin on Fri Dec 15 15:49:36 UTC 2023 , Edited by admin on Fri Dec 15 15:49:36 UTC 2023

PRIMARY

Merck Index

NCI_THESAURUS

C80325

Created by admin on Fri Dec 15 15:49:37 UTC 2023 , Edited by admin on Fri Dec 15 15:49:37 UTC 2023

PRIMARY

Related Record Type Details


					7U1LPD9FR4

ZOLEDRONATE TRISODIUM ANHYDROUS

ANHYDROUS->SOLVATE


					70HZ18PH24

ZOLEDRONIC ACID ANHYDROUS

PARENT -> SALT/SOLVATE

Related Record Type Details


					70HZ18PH24

ZOLEDRONIC ACID ANHYDROUS

ACTIVE MOIETY

Details

SMILES

InChI

DescriptionSources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/21386lbl.pdf

Originator

Approval Year

Targets

Conditions

Approved Use

Launch Date

Approved Use

Launch Date

Approved Use

Launch Date

Approved Use

Launch Date

Approved Use

Launch Date

Cmax

AUC

T1/2

Doses

AEs

Overview

OverviewOther

Drug as perpetrator​

Drug as victim

PubMed

Patents

Sample Use Guides

Description
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/21386lbl.pdf

C_max

T_1/2

Drug as perpetrator